No registrations found.
ID
Source
Health condition
Patients treated with chemotherapy for a solid tumor
Patienten die behandeling krijgen met chemotherapie vanwege een solide tumor
Sponsors and support
Intervention
Outcome measures
Primary outcome
Relation between baseline MBL and incidence of febrile neutropenia (FN).
Secondary outcome
1. MBL genotype and relation FN;
2. Changes in MBL concentration;
3. Relate severity of FN with MBL levels.
Background summary
Measuring MBL prior to chemotherapy and at an episode of FN in patients receiving chemotherapy for a solid tumor.
Study objective
MBL deficiency might give rise to a higher chance of the occurence of febrile neutropenia.
Study design
Prior to cycle 1 and prior to cycle 2 and during FN measurement of MBL.
Intervention
N/A
A.P. Hamberg
Rotterdam 3045 PM
The Netherlands
+31 (0)10 4616145
p.hamberg@sfg.nl
A.P. Hamberg
Rotterdam 3045 PM
The Netherlands
+31 (0)10 4616145
p.hamberg@sfg.nl
Inclusion criteria
1. Patients commencing chemotherapy treatments for a solid tumor;
2. Written informed consent.
Exclusion criteria
1. Previous participation in the current study;
2. Patients < 18 yrs;
3. Patients not able to give informed consent;
4. Patients receiving chemotherapy in a weekly schedule or a bi-weekly dose dense schedule;
5. Patients receiving granulocyte growth factor support (G-CSF);
6. Patients receiving a treatment with an individualized risk (combination of scheme and presence of risk factors) on FN over 20% according to the EORTC guidelines;
7. Patients receiving (prophylactic) antibiotics;
8. Patients receiving concomittant radiotherapy.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL3246 |
| NTR-old | NTR3398 |
| Other | SFG : 2011/42 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |